WASHINGTON, March 16, 2020 /PRNewswire/ --

WASHINGTON, March 16, 2020 /PRNewswire/ -- Research & Innovation, a boutique consulting firm focused on delivering actionable insights to advise organizations through their largest challenges, has launched a direct-action stimulus plan in response to the economic effects of the Coronavirus pandemic in the United States. This program f

INDIANAPOLIS, March 16, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has begun shipping the first allotment of its cobas® SARS-CoV-2 Test for COVID-19 (coronavirus) to a network of hospital and reference laboratories across the U.S. to enable automated, high-volume patient testing. Shipping of the initial 400,000 test kits

MINNEAPOLIS, March 16, 2020 /PRNewswire/ -- Two Children's Minnesota employees were honored in Becker's Hospital Review 2020 list of '

TEMPE, Ariz., March 16, 2020 /PRNewswire/ -- Benchmark Electronics, Inc. (NYSE: BHE) today announced that its Board of Directors declared a quarterly dividend of $0.16 per share, payable on April 14, 2020 to shareholders of record at the close of business on March 31, 2020.

STATESVILLE, N.C., March 16, 2020 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU). 

OLDWICK, N.J., March 16, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced a temporary pause in the randomization of patients with newly diagnosed type 1 diabetes (T1D) into its global Phase 3 PROTECT study of PRV-031 (teplizumab). This pa

UPPSALA, Sweden, March 16, 2020 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Thursday 16 April 2020, at 16.00 pm in Orexo's facilities at Rapsgatan 7E in Uppsala, Sweden. Due to the COVID

SAN FRANCISCO, March 16, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million

BRIDGEWATER, N.J., March 16, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided a general business update.Submission of New Drug Application for ARIKAYCE® (amikacin liposome inhalation suspension) in